What Actually Happens When THC Enters the Body

Before we begin, a clarification that matters.

This post is not about whether THC is good or bad, legal or illegal, or whether you should or should not use it. Those are separate conversations. This post is about biology. Specifically, what happens at the cellular level when THC enters a human body, why those things happen, and what understanding the mechanism reveals about the system the body was always designed to run without any external input at all.

If you have ever used cannabis and noticed it worked, this post explains why. If you have ever used it and noticed it stopped working as well over time, this post explains that too. And if you have never used it and have no intention of doing so, this post may still be the most useful thing you read about your own biology this year, because the system THC acts on is running in your body right now, and the question of whether it is running well has nothing to do with cannabis.

Step 1: THC Reaches the Bloodstream

Whether inhaled, consumed as an edible, or taken sublingually, THC is a lipophilic molecule. Lipophilic means it dissolves in fat rather than water. This is not a minor chemical detail. It is the first clue about which system THC is interacting with, and why.

Because THC is fat-soluble, it crosses the blood-brain barrier easily and distributes rapidly into lipid-rich tissues throughout the body: the brain, the peripheral nervous system, the liver, adipose tissue, skeletal muscle, and immune tissue. It goes where the fat is. ESTABLISHED

This is mechanistically significant because the system THC is about to interact with is also fat-based. The endocannabinoid system synthesizes its signaling molecules on demand from the fat in cell membranes. THC is lipophilic because the system it mimics is lipid-dependent. The fat in the membrane is part of why THC gets where it is going so efficiently.

Step 2: THC Meets the Endocannabinoid System

The Endocannabinoid System, or ECS, is a regulatory network expressed in virtually every tissue in the human body. It governs inflammation, pain threshold, sleep architecture, stress response, immune function, appetite, and recovery. It does this through two primary receptors: CB1, found densely in the brain and peripheral nervous system, and CB2, found densely in immune tissue throughout the body.

The system was designed to run on molecules the body makes itself: anandamide and 2-AG, both synthesized on demand from cell membrane phospholipids. These are the body's own endocannabinoids. They are produced when the body needs them, used immediately, and then degraded by specific enzymes so the receptor returns to its resting state ready for the next signal. ESTABLISHED

THC binds directly to CB1 and, less potently, to CB2. It does not deliver a new instruction the receptor has never seen before. It occupies the same binding site the body's own anandamide would occupy, and produces effects along the same pathway, just stronger, longer-lasting, and without the rapid degradation anandamide undergoes.

Step 3: CB1 Activation and Its Effects

When THC binds CB1, the downstream effects are well-documented. Pain signals are modulated: CB1 in peripheral sensory neurons reduces the intensity and frequency of pain signals traveling to the brain. Nausea is suppressed: CB1 in the brainstem and gut reduces the emetic response that chemotherapy and other conditions produce. Appetite is stimulated: CB1 in the hypothalamus signals increased hunger. The stress response is dampened: CB1 in the amygdala and prefrontal cortex reduces the fear response and modulates cortisol output. Psychoactivity occurs because CB1 in the cerebral cortex alters perception, time experience, and associative thinking in ways that vary significantly by dose, membrane substrate quality, and individual receptor density. ESTABLISHED

Step 4: CB2 Activation and Immune Resolution

THC also binds CB2 receptors, the receptors expressed densely in immune tissue throughout the body. CB2 activation is the primary immune resolution mechanism of the ECS: it governs the transition of macrophages from their M1 pro-inflammatory state to their M2 pro-resolution state. When this transition completes, the inflammatory response stands down, the immune system stops attacking the tissue it was protecting, and the repair process begins. ESTABLISHED

This is why cannabis has historically been used for inflammatory conditions across cultures and centuries. The people using it did not know about CB2 receptors or macrophage polarization. They knew that it reduced inflammation in ways they could observe. The molecular mechanism was identified by research scientists in the late 20th century. The empirical observation preceded the explanation by thousands of years. ESTABLISHED

Step 5: FAAH Inhibition, the Body's Own Signal Gets Extended

THC does something beyond directly activating CB1 and CB2. It also indirectly increases the body's own endocannabinoid levels by inhibiting FAAH, the enzyme responsible for breaking down anandamide. When FAAH is inhibited, anandamide accumulates. The body's own endocannabinoid signal is extended and amplified alongside the THC signal. ESTABLISHED

This is part of the mechanism behind the "entourage effect" that the cannabis industry has discussed extensively. The minor cannabinoids and terpenes in full-spectrum cannabis products also modulate FAAH and related enzymes, which is why full-spectrum products often produce different effects than isolated THC. But the clinical evidence for the full commercial entourage effect concept does not hold up under scrutiny. A 2023 scoping review in Biomedicines found the existing studies contradictory and methodologically limited, with the clinical data leaning heavily on anecdotal and real-world evidence. A 2026 paper in the Internal Medicine Journal went further, concluding that no clinical or in vitro evidence supports the hypothesis and that it remains speculative pending well-designed trials. What is established is the FAAH inhibition mechanism of THC itself. (ESTABLISHED for FAAH inhibition; MECHANISTICALLY SOUND for the full entourage effect in humans)

Step 6: The Membrane Determines How Well Any of This Works

Here is the layer of the mechanism that almost no consumer education about cannabis addresses, and that is the most important single thing to understand about why THC works differently in different people and why it works differently in the same person over time.

CB1 and CB2 receptors are not floating freely in the cell. They are embedded in lipid raft domains within the cell membrane. Their density, clustering, coupling efficiency, and downstream signaling cascade all depend on the lipid composition of the membrane they sit in. MECHANISTICALLY SOUND

A receptor embedded in a DHA-adequate membrane, one built from dietary omega-3 fatty acids over the prior 90 to 120 days, responds to THC differently than the same receptor embedded in an omega-6 dominant membrane built from decades of industrial seed oil consumption. In a DHA-adequate membrane, the receptor couples more efficiently to the G-protein cascade it initiates. The THC signal travels further into the cell more completely. The downstream effects are more thorough and require less THC to achieve. MECHANISTICALLY SOUND

In an omega-6 dominant membrane, the receptor is embedded in a structurally inferior lipid raft environment. Coupling efficiency is reduced. The THC signal is generated but travels less completely into the cell. The same dose produces a blunted response. The person finds themselves needing more to achieve the same effect.

Step 7: Receptor Downregulation and Why THC Stops Working as Well

When CB1 is chronically activated by exogenous THC, the cell does what cells do when any receptor is persistently stimulated: it pulls the receptor from the membrane surface into the cell interior to protect itself from over-stimulation. Receptor density on the cell surface decreases. More THC is required to produce the same effect because fewer surface receptors are available to receive the signal. This is tolerance. ESTABLISHED

Understanding why this happens differently with THC than with the body's own endocannabinoids is the key insight. Anandamide, the body's primary CB1 ligand, is synthesized on demand and degraded rapidly by FAAH within seconds to minutes of use. It activates the receptor in a pulse and disappears, allowing the receptor to return to the surface and remain sensitive for the next signal. THC, by contrast, is fat-soluble and persists in the body for hours to days, producing sustained receptor activation that triggers the downregulation response. ESTABLISHED

The body evolved the ECS as a pulsatile signaling system. Brief, precise, demand-driven activation. THC produces sustained activation. The difference in timing is a significant part of why tolerance develops with regular cannabis use in a way it does not develop with the body's own endocannabinoid production when that production is adequate. MECHANISTICALLY SOUND

Step 8: When THC Stops, the Gap Becomes Visible

When THC is discontinued after regular use, the body is left with several things simultaneously: downregulated CB1 receptors that need time to return to the cell surface, a depleted endogenous anandamide pool because FAAH inhibition has been compensating for what the body was not generating on its own, and the same underlying substrate deficit that was present before THC was introduced. The external signal is gone. The infrastructure was not rebuilt. The conditions that made the signal necessary remain unchanged. (ESTABLISHED for receptor downregulation; MECHANISTICALLY SOUND for the substrate gap)

This is the mechanism behind cannabis withdrawal, which does not produce the acute dramatic withdrawal of opioids but produces a gradual return of the symptoms the THC was managing: disrupted sleep, increased anxiety, reduced appetite, the return of pain that had been modulated. The body is trying to run a regulatory system with downregulated receptors and a depleted endogenous substrate pool. It takes weeks to months for the receptor density to return to baseline and for endogenous production to be asked to sustain tone on its own again. ESTABLISHED

The Signal vs. Substrate Distinction

Every pharmaceutical, supplement, and botanical product that interacts with the ECS is a signal intervention. It modifies what the system's messages say. THC tells CB1 to modulate pain. CBD tells FAAH to slow down and let anandamide accumulate. Pharmaceutical CB1 blockers like rimonabant told CB1 to stop activating so aggressively in visceral adipose tissue. All of these are signal-level interventions. They change the message. They do not change what the messaging infrastructure is built from.

The messaging infrastructure is the cell membrane. The membrane is built from dietary fat. The quality of the dietary fat consumed over the prior 90 to 120 days determines the lipid composition of every CB1 and CB2 receptor environment in the body. This is the substrate layer, and it is the layer that every signal-level intervention acts on top of without addressing.

THC cannot change what the membrane is built from. Food does. When the membrane improves through changes in dietary fat quality, the receptors respond more efficiently to both exogenous THC and endogenous anandamide. When the substrate is restored sufficiently, the body begins producing enough of its own endocannabinoid signaling to maintain regulatory function without external activation. The trucks become less necessary not because the signal is being blocked but because the factory is running well enough to make its own.

What the Evidence Actually Shows for THC Therapeutically

To be precise about what the peer-reviewed literature supports, the honest map looks like this:

The One Thing THC Does Not Do

THC does not cure anything. This is not a hedge or a legal disclaimer. It is the accurate state of the peer-reviewed evidence. THC manages symptoms through signal-level CB1 and CB2 activation that requires continued administration to maintain. When the administration stops, the signal stops. The condition the signal was managing does not change. The body is back where it started, minus whatever receptor downregulation has occurred in the interim.

This is not a criticism of THC as a therapeutic compound. It is a precise statement of what signal-level interventions can and cannot do. They work. They work through real mechanisms in real people with real conditions. And they do not address the substrate deficit that is often the upstream reason the endogenous signal was insufficient to begin with.

The body was designed to regulate pain, inflammation, sleep, and immune function without external activation. The evidence that it can do this is everywhere: in the populations that maintained traditional food cultures and maintained extraordinary health outcomes into advanced age without any access to cannabis products or pharmaceutical management. They were not managing chronic conditions. Their endogenous systems were running adequately from the substrate those food cultures delivered.

THC is the most vivid available demonstration that the ECS receptor system exists and responds to activation. It is a proof of concept for a system the body was always designed to run itself. The question it leaves unanswered, the one that matters most for anyone whose symptoms it is managing, is: what does the body need to activate that system from within?

Not a product. Raw material. The quality of the fat in your cell membranes, built from the quality of the fat in your food, determines how well the system the THC is activating can run on its own.

That is the question this practice works on.